First National Bank Of Omaha Pacira Bio Sciences, Inc. Transaction History

First National Bank Of Omaha

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$25.5 - $31.51 $51,994 - $64,248	-2,039 Reduced 21.14%	7,608 $217,000
Q1 2024 May 10, 2024	SELL	$27.7 - $35.48 $453,365 - $580,701	-16,367 Reduced 62.92%	9,647 $281,000
Q4 2023 Feb 13, 2024	BUY	$26.32 - $34.31 $68,537 - $89,343	2,604 Added 11.12%	26,014 $877,000
Q3 2023 Nov 14, 2023	SELL	$30.68 - $40.09 $40,712 - $53,199	-1,327 Reduced 5.36%	23,410 $718,000
Q2 2023 Aug 14, 2023	BUY	$36.12 - $47.5 $5,129 - $6,745	142 Added 0.58%	24,737 $991,000
Q1 2023 May 03, 2023	BUY	$35.53 - $43.38 $9,024 - $11,018	254 Added 1.04%	24,595 $1 Million
Q4 2022 Feb 08, 2023	SELL	$38.19 - $57.45 $30,552 - $45,960	-800 Reduced 3.18%	24,341 $940,000
Q3 2022 Nov 14, 2022	BUY	$51.24 - $58.89 $9,633 - $11,071	188 Added 0.75%	25,141 $1.34 Million
Q2 2022 Sep 06, 2022	SELL	$51.49 - $81.64 $9,628 - $15,266	-187 Reduced 0.74%	24,953 $1.45 Million
Q1 2022 May 25, 2022	BUY	$60.03 - $76.49 $101,330 - $129,115	1,688 Added 7.2%	25,140 $1.92 Million
Q4 2021 Feb 11, 2022	BUY	$47.97 - $62.21 $19,859 - $25,754	414 Added 1.8%	23,452 $1.41 Million
Q3 2021 Nov 12, 2021	BUY	$54.64 - $61.3 $781,789 - $877,080	14,308 Added 163.89%	23,038 $1.29 Million
Q1 2021 May 06, 2021	SELL	$59.31 - $78.82 $62,394 - $82,918	-1,052 Reduced 10.75%	8,730 $612,000
Q4 2020 Feb 18, 2021	BUY	$50.47 - $66.26 $47,795 - $62,748	947 Added 10.72%	9,782 $585,000
Q3 2020 Nov 06, 2020	BUY	$51.97 - $63.0 $459,154 - $556,605	8,835 New	8,835 $531,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of First National Bank Of Omaha, based on Form 13F filings with the SEC.

Stay updated on First National Bank Of Omaha with notifications on news.